Blue Port Legal can boast the expertise of Nora Kessler, who advises pharmaceutical and medical clients on a range of trademark, patent law, and other intellectual property matters, both contentious and non-contentious.

The breadth of Clifford Chance’s healthcare and life sciences practice is illustrated by a client roster spanning pharmaceutical and medical device manufacturers, hospitals and care homes, and global healthcare companies. The firm’s instructions cover competition and regulatory disputes, establishment and governance of distribution models at the European and international scale, transactions and post-transactional compliance and drug advertising, marketing and licensing questions. In 2025, the practice has recently expanded into AI and blockchain-based healthcare projects and solutions. The team includes members with multidisciplinary expertise: Gunnar Sachs is an IP law expert who also leads on digitalisation projects, Peter Dieners, who excels in the field of healthcare regulatory compliance, and Ulrich Reese, who has decades of experience in copyright disputes and proceedings. Torsten Syrbe is a key international contact, and Manuela Steininger advises on pharmaceutical marketing regulations.

Hogan Lovells International LLP remains at the technological forefront of the life sciences sector, integrating advice on data protection, cybersecurity and AI regulations into a comprehensive digital health advisory practice for pharmaceutical and medical technology manufacturers and investors. The practice is also strong in traditional areas of healthcare law, including compliance and competition law advice, financing rounds and sales, market entries and expansions of global health companies into Europe, and representation in and out of court in medical law cases. Jörg Schickert leads on complex internal regulatory matters and contract negotiations, Arne Thiermann is experienced in transactions and has an emergent AI practice, Matthias Schweiger leads on product liability proceedings for pharmaceutical companies, and Tanja Eisenblätter is an experienced litigator in the medical field.

Covering the entire scope of the healthcare and life sciences sector, Taylor Wessing has strengths in long-term healthcare transactional advice; ongoing patent, licensing and employment law counselling; and contentious drug advertising and competition law cases. With particular strength in disputes, the practice has led in some of the most prominent cases of patent infringement and product liability litigation in the pharmaceutical and medical device industry, where Henning Moelle  is a leading name; a recent work highlight is representing major global pharmaceutical firms on Covid-19 vaccine liability proceedings. On the transactional side of the team, Oliver Kirschner and Oliver Klöck  have experience in healthcare company and facility M&A on the buy and sell-sides, and Daniel Tietjen leads in matters concerning drug advertising law.

With particular strength in overseeing major healthcare and life sciences transactions, A&O Shearman advises on the acquisitions and disposals of medical and biotech companies, providing comprehensive advice on market regulations, internal restructuring, and post-M&A litigation for clients including private equity investors and healthcare industry leaders alike. The practice group also advises on industry regulations concerning medical devices and drug advertising. Sector lead Alexander Veith is a transactional specialist with experience in corporate law matters at the national and international level as well as in IP disputes, and Eda Zhuleku excels in life sciences regulatory matters such as product reimbursement and clinical trial approvals.

Baker McKenzie has a highly diversified healthcare offering, with the firm instructed on behalf of major clients in public procurement and distribution platform establishment; pharmaceutical advertising, marketing and legal proceedings; and a range of sales and acquisitions of shares and portfolios in hospital groups and life science tech companies. Over the last year the practice has been instructed on an array of damages claims before the courts by international pharmaceutical firms. With extremely broad experience across multiple disciplines, practice leader Thilo Räpple is valued for his contentious and non-contentious experience. Other key names include Julia Braun, who is specialised in a variety of healthcare and life sciences transactions and financings, and Martin Altschwager, a regulatory and contract law expert.

Leveraging the strengths of the firm’s European and international breadth, CMS‘ multidisciplinary team has a notable emphasis on market entries and healthcare transactions, and the practice’s individuals are also experienced in EU data and pharmaceutical regulations, having tried a number of cases before the ECJ. Interpretation of the interaction between data protection and EU medical device regulations has been a primary focus in the past year. Practice head Roland Wiring is skilled in drug advertising mandates, healthcare service digitalisation projects and product liability disputes. Other prominent individuals in the practice include Jörn Witt, who is retained by pharmaceutical companies on long-term regulatory mandates, and Christoph Lächler is the practice’s resident healthcare M&A specialist.

Uniquely situated as a boutique law firm focusing on the healthcare sector, Dierks+Company places focus on the benefit assessment and price negotiation of medicinal products and devices, consulting in the field of health technology assessment, digital transformation in the healthcare sector and the design of new business models and German market entry, for clients ranging from university hospital groups to MedTech companies. Firm founder Christian Dierks is a specialist in medical device law, and Dominik Roters focuses on working with health insurance funds and in pharmaceutical law.

DLA Piper’s healthcare and life sciences practice works within the firm’s global network to act for leading pharmaceutical and biotech companies in complex regulatory and transactional mandates covering market launches and expansion, product commercialisation and renumeration model designs, and on an array of internal healthcare regulatory compliance questions. Dually qualified as a medical doctor and a lawyer, the practice is led by Kokularajah Paheenthararajah, who brings experience in complex patent and licensing litigation concerning future life sciences technology. The team can bring expertise from a range of different legal areas: corporate law specialist Moritz von Hesberg acts on cross-border healthcare M&A, and counsel Thilo Streit has relevant experience in regulatory matters.

Gleiss Lutz has particular experience in social security law and statutory health insurance issues, and also leads for pharmaceutical and medical device manufacturers and federal ministries alike in product liability and patent litigation proceedings. Other strengths of the group include contract design and negotiation, telemedical service operations, with an increased recent presence in the interaction between medical device law and AI regulations. Enno Burk has led on summary proceedings and has advises on German market entry, Reimar Buchner has unique experience acting for hospitals in health insurance proceedings, and Marco König and Christine Mattes provide support on public procurement and discount agreements for pharmaceutical companies.  Large-scale digitalisation projects of health insurance systems have been a recent area of focus for the practice.

Greenberg Traurig Germany gained significant strength in the healthcare and life sciences sector in 2025, with Stephan Rau, valued by clients in healthcare and private equity for his track record in complex M&A and financing matters, and Christian Rybak, a medical law and public healthcare policy expert, joining the firm from McDermott Will & Schulte and Ehlers Legal PartG mbB respectively. Work for clients spans regulatory compliance, licensing, litigation, IP/tech/data protection, and tax advice. Other prominent members include general corporate law specialist Björn Biehl, and domestic and EU regulatory expert Julian Bartholomä.

Latham & Watkins LLP advises industry-leading healthcare and pharmaceutical companies on a complex range of transactions and corporate matters. These include acquisitions of specialised biotech companies and healthcare retailers, medical and pharmaceutical market entries for global clients, and start-up financing rounds and share sales for venture capital and private equity funds. Furthermore, the practice has also acted in regulatory proceedings. Leading a dedicated team that also offers legal expertise in tax, competition, employment and IP law, Henning Schneider is a healthcare and life sciences transactional specialist, and he is joined on a diverse range of corporate law matters by Christoph Engeler and Henrietta Ditzen. Another leading name is Deniz Tschammler, who leads on novel platform and business management establishment matters for life science technology companies.

Luther Rechtsanwaltsgesellschaft mbH‘s healthcare and life sciences sector group brings together expertise in transactions as well as employment, procurement and competition law to advise a wealth of healthcare clients on regulatory and corporate law issues. With a background in M&A, Oliver Kairies provides support for medical care and hospital groups on acquisitions and internal restructurings, and also provides ongoing general medical law advice. The multidisciplinary team also includes co-leader Christian Burholt, a competition and compliance specialist, as well as Elisabeth Kohoutek, a specialist in healthcare digitalisation and medical device law, and Thomas Willaschek, an outpatient care expert who joined the firm from D+B Rechtsanwälte Partnerschaft mbB in June 2024.

Healthcare boutique NOVACOS Rechtsanwälte has an extremely broad healthcare offering and client roster. With strong transactional capability, regulatory advice on market access is a particular strength of the practice, with the firm well-situated to advise on EU legislation concerning combination discounts and pharmaceutical pricing negotiations, with Alexander Natz and Maria Heil the key contacts in this area. On the regulatory front, Christian Stallberg leads in court proceedings in social law cases and provides general regulatory advice on IP and pharma law matters.

With a traditional strength in IT and data law, Osborne Clarke works on behalf of biotechnology, pharmaceutical, and digital health industry leaders on regulatory, marketing, and corporate matters. The design and implementation of SaaS products for processing patient data has recently been a prominent area for the firm. The practice group is home to a range of specialists: group leader Andrea Schmoll handles contractual matters and representation in life science developmental projects; Tim Reinhard is particularly valued for his expertise in the intersection between medical technology regulations and IP law; and Tobias Rothkegel is a data protection expert who acts on cybersecurity and AI questions for cloud technology developers in the healthcare space.

Raue stands out for its particularly strong capability in contentious healthcare matters for hospital groups and online health and pharmaceutical platforms, and the practice also brings experience in corporate law from across the firm to advise in investments, financings, and acquisitions of medical and life science firms for strategic investors, as well as for advisory work on buy-and-build strategies. The practice heads are Katharina Wodarz, whose experience in pharmaceutical law is implemented in healthcare transactions and litigation, and Maren Bedau, who leads on major hospital financings and consolidations as well as holding company establishment. Another name of note is Jörg Adam, who has unique experience in state aid law.

Bird & Bird LLP‘s cross-sector team brings individuals with backgrounds in employment, IP, and commercial law together to represent medical and pharmaceutical product manufacturers and biotechnology research firms in regulatory and contentious matters. Novel recent matters for the practice include guidance on the legal considerations concerning cannabis-derived products. Boris Kreye is highly experienced in patent infringement litigation, Alexander Csaki is valued by clients for his work in public procurement and with health insurance funds, and Fabian Niemann has experience in leading in complex data protection matters for healthcare providers.

Integrating specialisms from across the firm, the mainstays of Covington & Burling LLP‘s life sciences practice include corporate and regulatory advice on major transactions, compliance advice on medical device and pharmaceutical regulations, and legal action concerning product liability before German and EU courts. Clients include global life sciences pharma and medical technology companies as well as medical device manufacturers. Adem Koyuncu marshals unique experience as both a physician and a lawyer to act on instructions spanning drug advertising law, data protection regulations, and legal issues concerning clinical trials.

Regulatory healthcare and life sciences advice is the focus of D+B Rechtsanwälte Partnerschaft mbB as a firm, with cross-sector strength in depth in pharmaceutical, medical, corporate, and IT law, applied on behalf of hospital and facility operators and investors. In addition to its strength in regulatory compliance advice, the practice has also led in large social law proceedings concerning pricing. Life sciences specialist Ulrich Grau acts for a client base including pharmaceutical manufacturers and private equity funds, and Christian Pinnow leads on regulatory issues concerning outpatient and medical care centres and on the development of digital health platforms.

Dentons employs international and multidisciplinary expertise to represent hospitals, pharmaceutical companies, and online service providers in a host of transactional and regulatory matters. The team covers the main areas of healthcare and life sciences: Ilka Mehdorn drafts complex industry-specific contracts concerning product distribution and clinical trials and also leads on ongoing regulatory compliance mandates; corporate lawyer Christof Kautzsch has recently led on a number of prominent mergers of university hospital groups, and Peter Braun is valued by hospitals and laboratory groups for his public procurement expertise.

Retained by leading pharmaceutical and life sciences companies for a comprehensive regulatory and transactional service, Eversheds Sutherland‘s life sciences practice is integrated into a global network. Recent work highlights include post-IPO regulatory support and the support on the development of novel treatments. Practice head Tobias Maier has a background in IP law and is a specialist in applying his experience to R&D projects for pharmaceutical and biotechnology firms, Anette Gärtner is a specialist in medical device patent litigation, and Nils Müller integrates experience in data protection and IT law to represent medical technology firms.

King & Spalding LLP has a specialty in representing pharmaceutical manufacturers and healthcare companies in contentious matters, with particular strengths in parallel import, competition law, and trademark rights disputes. Instructions come in at the European level, and the firm has recently acted in number of landmark proceedings before the ECJ. Practice leader Ulf Grundmann has decades of experience in medical device and pharmaceutical law, which is also applied to internal regulatory matters.

Complex and cross-border healthcare transactions are Linklaters‘ greatest strength in the healthcare and life sciences sector, and clients include global investors, healthcare holding companies, and tech leaders. The practice employs a depth of expertise across legal disciplines: Rupert Bellinghausen is well-versed in arbitration and commercial litigation and leads on damages claims and medical product liability litigation; corporate law specialist Timo Engelhardt leads on high-value M&A; Julia Schönbohm brings expertise in IP and TMT law to act on healthcare data protection matters; and Jana Hager is renowned for her work in regulatory product law, and also assists on transactions.

McDermott Will & Schulte specialises in providing regulatory advice when working for digital health and pharmaceutical service providers, and the practice also has relationships with strategic investors. At the helm of the practice, Jana Grieb leads on a wide range of matters including market entry, post-transactional compliance management, and general health law matters, while Monika Richter, who was promoted to partner in 2024, specialises in healthcare transactions and co-operation agreements.

In the healthcare and life sciences space, Meisterernst Rechtsanwälte specialises in drug advertising matters, spanning market launch advisory work, contract negotiations, and competition proceedings. Recent matters on which the firm has led on include advisory work on the interaction between German pharma law and EU regulations. Practice group leader Christian Tillmanns has a track record in acting for pharmaceutical clients in contentious advertising and distribution law matters, and his expertise also covers competition law and general advice on healthcare and pharmaceutical regulatory compliance. Markus Fuderer acts on a diverse range of matters, with a particular strength in medical devices law.

Möhrle Happ Luther is instructed by global pharmaceutical producers and digital health platforms in regulatory matters and contentious proceedings. Notable recent instructions have centred around vaccine acquisition, approval, and market entry preparation. The practice is co-headed by life sciences specialist Henning Anders, who has strong credentials in disputes concerning social law, questions of reimbursement and benefit assessments, and in medical and pharmaceutical product launches. Alongside Anders, Julia Luther is a prominent name in the field of competition and drug advertising law, and Joachim Jung brings experience in IP law to complex disputes.

With deep industry knowledge in the regulatory field, strengths of Noerr‘s healthcare practice include M&A and sales at the German and international scale, ongoing corporate advice to healthcare providers, and the IP and licensing elements of co-operation agreements. Evelyn Schulz has broad regulatory experience, covering areas such as cannabis, product compliance, and tele-health, and Isabel Jakobs assists in both transactions and in product liability disputes concerning medical devices.

With a roster of clients in the pharmaceutical and medical device industries, Oppenländer Rechtsanwälte advises on therapeutic product and competition law disputes, licensing matters concerning drug advertising and manufacturing, as well as contract law elements of supplier agreements, with particular strength in acting for pharmacies. The practice’s leading individuals have experience in major drug advertising disputes before the Hamburg Regional Court. Christina Koppe-Zagouras and Timo Kieser have experience in IP disputes, and Katharina Köbler leads in a gamut of regulatory matters.

PPP Rechtsanwälte has developed a broad healthcare practice, with clients including hospital groups, university hospitals and private clinics, offering services spanning competition and preparation for M&A, internal restructurings and contract negotiations, as well as defence against damages claims. Andreas Penner specialises in consulting on all forms of transactions and on public health questions, and Felix Reimer is a name to note for contract negotiations.

A leading firm in the area of contentious healthcare regulatory and drug advertising matters, Preu Bohlig & Partner is often instructed by major pharmaceutical product and medical device manufacturers on complex regulatory cases. The firm's caseload spans both domestic and European court systems and covers marketing protections, product liability, and competition law. Peter von Czettritz has comprehensive experience in proceedings against the European Commission in an array of areas of medical law, and he is assisted by Tanja Strelow.

Tsambikakis & Partner Rechtsanwälte has a longstanding reputation in the field of medical criminal law, and is regularly instructed by prominent hospitals and private clinics, as well as medical professionals and directors on criminal defence cases. In addition, the firm has capabilities covering internal investigations and risk-avoidance counselling. With experience in white-collar crime, Michael Tsambikakis is an established name in healthcare and pharmaceuticals, and other key names include Karolina Kessler and Markus Gierok. Daniela Etterer departed the firm for an in-house position in January 2025.

WilmerHale‘s practice is valued by clients in pharmaceuticals and life sciences on regulatory questions relating to clinical trials, licensing and destruction agreements, with a particular strength in contentious cases. Hans-Georg Kamann is a highly experienced litigator with a growing regulatory practice, and Peter Gey has in-depth knowledge on the application of European and German competition law to matters pertaining to pharmaceutical advertising and distribution.

GÖRG Partnerschaft von Rechtsanwälten mbB leverages its capabilities in corporate transactions, employment law, and public procurement to support healthcare and life science groups, public sector clients, and real estate investors on an array of internal regulatory and legal concerns. John-Patrick Bischoff is a transactional specialist highly regard by private equity clients for his experience in facility acquisitions, and Marc Schüffner leads on complex healthcare regulatory matters. Katja Kuck is active at the intersection of healthcare and data protection law.

GSK Stockmann works with national and local hospital operators, healthcare property investors as well as pharmaceutical and medical technology companies on distribution, licensing, and tender processes. The practice also has experience in public procurement, healthcare M&A, and IT and medical device law. Maritheres Palichleb leads on real estate and asset management matters for healthcare providers, and Jenny Mehlitz is the practice’s expert on procurement and digitalisation processes for hospitals.

Heuking leads on a diverse array of transactions in the healthcare and life sciences sector, advising on regulatory compliance and covering sales and acquisitions, market entry and expansion, and international platform structurings. Oliver Treptow and Florian Brombach are leading contacts for hospital groups, laboratories and facilities, as well as investors on the seller and buyer’s side of transactions.

Hospital and panel doctors law are the strengths of michels.pmks Rechtsanwälte‘s healthcare practice, providing medical care centres, clinics and university hospital groups with ongoing strategic and operational advice. Kerrin Schillhorn brings experience in administrative and social law to hospital planning and co-operation agreement matters, and Jens-Peter Jahn represents care centres and outpatient facilities in a range of legal proceedings.

Oppenhoff acts in the healthcare and life sciences sector on both market entry and expansions for healthcare product distributors, where the firm provides complex cross-border regulatory advice, and has a particular strength in representing pharmaceutical companies in tax-related matters. Franziska Katterbach was appointed partner in October 2024, and covers commercial, transactional, and regulatory matters for healthcare companies.

Redeker Sellner Dahs counts federal ministries, large healthcare providers and health insurance companies as clients and is reputed for representation in major medical, data protection, and product liability litigation in courts up to the ECJ. Christian Eckart has strong credentials in the application of public commercial law to healthcare disputes on behalf of public and government bodies, and Cornelius Böllhoff advises on a wide range of disputes concerning healthcare data protection and digitalisation.

Rittershaus provides corporate and medical law advice for clients in the pharmaceutical and medical industries, ranging from assisting on share acquisitions and sales to defense on liability and regulatory proceedings for manufacturers and distributors of healthcare products. Practice leader Wolf-Henrik Friedrich is experienced in drug advertising law and in life science transactions.

SKW Schwarz works with medical device manufacturers, healthcare providers and pharmaceutical companies on contentious and non-contentious procurement and tender applications as well as on transactions, integrating experience from the firm’s IT and digital business teams. Oliver Stöckel leads the team and is an experienced IP and competition litigator in the healthcare and life sciences sectors.

von BOETTICHER Rechtsanwälte Partnerschaftsgesellschaft mbB is renowned for their work for pharmaceutical and life sciences companies, bringing expertise in drug advertising, patent, IP and copyright law to a range contentious matters and transactions. These include medical insolvency proceedings, contract negotiations, advice on the launching of new healthcare products, and the acquisition and management of portfolios. Claudia Böhm and Anselm Brandi-Dohrn lead on matters of advertising law and licensing agreements respectively.